Sugi Predict

Sugi Predict / Compounds / SCHEMBL2937513

SCHEMBL2937513

SCHEMBL2937513

CNc1cnc2ccccc2c1CN1C(=O)N(c2ccc(OC(F)(F)F)cc2)C(=O)C12CC2

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 4/20 0.42
▸ IGF1R P08069 2/20 0.39
▸ ENPP2 Q13822 1/20 0.34
▸ CTNNB1 P35222 1/20 0.33
▸ TCF7L2 Q9NQB0 1/20 0.33
▸ MCHR1 Q99705 7/20 0.33
▸ NTRK1 P04629 1/20 0.33
▸ RAF1 P04049 1/20 0.33
▸ LCK P06239 1/20 0.33
▸ RET P07949 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ KIT P10721 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ MAP3K20 Q9NYL2 1/20 0.33
▸ RIPK3 Q9Y572 1/20 0.33
▸ PTGER4 P35408 1/20 0.33
▸ LIPE Q05469 1/20 0.33
▸ GPR139 Q6DWJ6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2937271 0.90 IGF1R (0.49) IGF1R
SCHEMBL2936711 0.89 GCGR (0.42) GCGRIGF1RENPP2MCHR1NTRK1
SCHEMBL2939719 0.88 GCGR (0.41) GCGRIGF1RMCHR1CYP3A4LIPE
SCHEMBL2943023 0.87 GCGR (0.41) GCGRIGF1RMCHR1CYP3A4
SCHEMBL2936895 0.87 GCGR (0.41) GCGRIGF1RENPP2MCHR1NTRK1
SCHEMBL2939105 0.87 GCGR (0.42) GCGRIGF1RMCHR1PTGER4LIPE
SCHEMBL2940723 0.86 IGF1R (0.46) IGF1RNTRK1
SCHEMBL2935293 0.86 GCGR (0.41) GCGRIGF1RENPP2MCHR1NTRK1
SCHEMBL2939362 0.86 IGF1R (0.56) GCGRIGF1RMCHR1
SCHEMBL2937833 0.83 GCGR (0.39) GCGRIGF1RENPP2MCHR1LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 GCGR 2462/4885IGF1R 1595/4885ENPP2 3905/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA GCGR 2407/4885IGF1R 962/4885ENPP2 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.